AUTHOR=Zhou Hui-Sheng , Su Yong-Feng , Wang Jun , Hu Ya-Lei , Wang An , Xu Lei , Wang Yi-Zhi , Zheng Xuan , Li Yu-Qing , Min Kai-Li , Gao Chun-Ji , Liu Dai-Hong , Gao Xiao-Ning 

TITLE=Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1533467

DOI=10.3389/fimmu.2025.1533467

ISSN=1664-3224

ABSTRACT=IntroductionAnti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab with a hypomethylating agent (HMA) plus CAG regimen in treating patients with r/r AML, with an increased sample size and in comparison, with a historical control group for more reliable data support (ClinicalTrials.gov identifier NCT04541277).MethodsThe study included a total of 37 patients with r/r AML who received the tislelizumab + HMA + CAG regimen.ResultsThe overall response rate was 69.4%, with a median overall survival of 12.1 months and event-free survival of 6.2 months. Multivariate analysis revealed that patients aged 40 or above exhibited a higher response rate, while those with lower leukemia burden (bone marrow blast percentage <40%) demonstrated improved overall survival and event-free survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation was associated with extended event-free survival. Grade 2-3 immune-related adverse events were observed in 8.5% of patients, and no deaths were directly attributed to these events. After propensity score matching, the inclusion of tislelizumab appeared to positively influence the overall response rate and event-free survival compared to historical controls treated with HMA + CAG regimen.DiscussionOverall, the combination regimen improved response rates while maintaining low incidence and severity of immune-related adverse events for r/r AML patients.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT04541277.